+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment



Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment



Journal of Neuroinflammation 13(1): 131



Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative motor neuron disease that involves activation of the immune system and inflammatory response in the nervous system. Reduced level of the immuno-modulatory and anti-inflammatory protein alpha-1-antitrypsin (AAT) is associated with inflammation-related pathologies. The objective of the present is to determine AAT levels and IL-23 in the cerebrospinal fluid (CSF) of ALS patients and control group. CSF samples from newly diagnosed ALS patients and age-matched controls were analyzed for AAT and IL-23 by ELISA and magnetic luminex screening, respectively. A statistically significant reduction of 45 % in mean AAT levels was observed in the CSF of ALS patients (21.4 μg/ml) as compared to the control group (mean 38.8 μg/ml, p = 0.013). A statistically significant increase of 30.8 % in CSF mean levels of the pro-inflammatory cytokine IL-23 was observed in ALS patients (1647 pg/ml) in comparison to the controls (1259 pg/ml, p = 0.012). A negative correlation coefficient (r = -0.543) was obtained by linear regression analysis of the two measured parameters (p = 0.036). Reduced AAT and elevated IL-23 CSF levels support the notion of neuroinflammatory process occurring in ALS patients. Increasing AAT levels in the patients' nervous system should be further investigated as a new therapeutic approach and a novel potential tool for ALS treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 058716119

Download citation: RISBibTeXText

PMID: 27245439

DOI: 10.1186/s12974-016-0589-4


Related references

Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 119(5): 341-344, 2008

Cerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosis. Journal of Neural Transmission 105(6-7): 703-708, 1998

Reduced lumbar cerebrospinal fluid corticotropin releasing factor (CRF) levels in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica 74(1): 72-74, 1986

Epidermal growth factor in human cerebrospinal fluid reduced levels in amyotrophic lateral sclerosis. Journal of Neurology 233(6): 376-377, 1986

T4, T3 and rT3 levels in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Neurology 236(1): 57-59, 1989

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging 67: 21-22, 2018

High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica 72(1): 61-64, 1985

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging 67: 21-22, 2018

Decreased chloride levels of cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences 285(1-2): 146-148, 2010

Decreased cerebrospinal fluid cytochrome c levels in patients with amyotrophic lateral sclerosis. Scandinavian Journal of Clinical and Laboratory Investigation 67(3): 264-269, 2007

Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. International Journal of Clinical and Experimental Pathology 8(5): 5419-5426, 2016

Decreased cerebrospinal fluid cGMP levels in patients with amyotrophic lateral sclerosis. Journal of Neural Transmission 111(2): 167-172, 2004

Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica 136(2): 145-150, 2016

Neurofilament Subunit L Levels in the Cerebrospinal Fluid and Serum of Patients with Amyotrophic Lateral Sclerosis. Neuro-Degenerative Diseases 18(2-3): 165-172, 2018

RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 8(5): 283-287, 2007